Dyadic International Inc (DYAI)

Dyadic International, Inc. is a NASDAQ-listed common stock company focused on biotechnology and industrial protein technologies. The company develops, produces, and commercializes industrial enzymes and other proteins in the United States and international markets. Its C1 platform is used in pharmaceutical applications, including the development and manufacture of pharmaceutical products, while its Dapibus platform is designed to support rapid development and large-scale production of enzymes, proteins, metabolites, and other biologic products for life sciences, food and nutrition, and bioindustrial uses. Dyadic is also advancing DYAI-100, a recombinant protein vaccine candidate based on the C1-SARS-CoV-2 program, which has entered phase 1 clinical testing. The company works through research, development, licensing, and joint development arrangements with partners including VTT Technical Research Centre of Finland, Rubic One Health, a global food ingredient company, Alphazyme, LLC, and Abic Biological Laboratories Ltd. Founded in 1979, Dyadic is headquartered in Jupiter, Florida.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.